Filgotinib联合甲氨蝶呤治疗活动性类风湿关节炎的剂量探索研究(DARWIN 1)
DARWIN 1是一项24周IIb期随机对照研究,纳入594例对甲氨蝶呤(MTX)应答不足的活动性类风湿关节炎(RA)患者,评估口服JAK1抑制剂filgotinib作为MTX附加治疗的疗效与安全性。结果显示,每日100 mg或200 mg filgotinib组第12周ACR20应答率显著高于安慰剂,疗效维持至24周,起效迅速且耐受性良好。
要点
- Filgotinib 100 mg每日一次或200 mg每日总量联合MTX可显著改善MTX应答不足的活动性RA患者症状。
- 疗效呈剂量依赖性且起效迅速,反应维持或改善至第24周,每日一次与每日两次方案间无显著差异。
- 治疗中出现的不良事件发生率与安慰剂组相似,未报告结核或机会性感染。
核心结论
- Filgotinib作为MTX附加治疗可改善活动性RA患者的体征和症状,起效迅速,且总体耐受性良好。
研究设计与样本
- 24周IIb期随机、安慰剂对照、剂量探索研究,594例接受稳定剂量MTX的中重度活动性RA患者按1:1:1:1:1:1:1随机接受安慰剂或filgotinib 50、100、200 mg每日一次或每日两次。
主要发现
- 第12周时,接受filgotinib 100 mg每日一次或200 mg每日总量(两种给药方案)的患者达到ACR20应答的比例显著高于安慰剂。
- 第12周其他关键终点(ACR50、ACR-N、基于28关节和C反应蛋白的疾病活动度评分、临床疾病活动指数、简化疾病活动指数和健康评估问卷-残疾指数)均显示100 mg或200 mg每日总量filgotinib优于安慰剂。
- 疗效反应维持或改善至第24周,多数疗效终点观察到快速起效和剂量依赖性反应,并与血红蛋白浓度升高相关。
- 每日一次与每日两次给药方案之间未见显著差异。
- 治疗中出现的不良事件发生率在安慰剂组和filgotinib组相似;严重感染在安慰剂组和filgotinib组分别发生于1例和5例患者;未报告结核或机会性感染。
关键数值与推荐
- 主要终点为第12周达到ACR20应答的患者百分比。
- 显著优于安慰剂的剂量包括filgotinib 100 mg每日一次和200 mg每日总量(每日一次或每日两次)。
临床怎么用
- 对于MTX应答不足的活动性RA患者,filgotinib 100 mg每日一次或200 mg每日总量联合MTX可作为候选治疗方案,需关注严重感染风险。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX. METHODS: In this 24-week phase IIb study, patients with moderate-to-severe active RA receiving a stable dose of MTX were randomised (1:1:1:1:1:1:1) to receive placebo or 50, 100 or 200 mg filgotinib, administered once daily or twice daily. Primary end point was the percentage of patients achieving a week 12 American College of Rheumatology (ACR)20 response. RESULTS: Overall, 594 patients were randomised and treated. At week 12, significantly more patients receiving filgotinib 100 mg once daily or 200 mg daily (both regimens) achieved an ACR20 response versus placebo. For other key end points at week 12 (ACR50, ACR-N, Disease Activity Score based on 28 joints and C reactive protein value, Clinical Disease Activity Index, Simplified Disease Activity Index and Health Assessment Questionnaire-Disability Index), differences in favour of 100 or 200 mg filgotinib daily were seen versus placebo; responses were maintained or improved through to week 24. Rapid onset of action and dose-dependent responses were observed for most efficacy end points and were associated with an increased haemoglobin concentration. No significant differences between once-daily and twice-daily regimens were seen. Treatment-emergent adverse event rates were similar in placebo and filgotinib groups. Serious infections occurred in one and five patients in the placebo and filgotinib groups, respectively. No tuberculosis or opportunistic infections were reported. CONCLUSIONS: Filgotinib as add-on to MTX improved the signs and symptoms of active RA over 24 weeks and was associated with a rapid onset of action. Filgotinib was generally well tolerated. TRIAL REGISTRATION NUMBER: NCT01888874.
引用
- Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2016. PMID: 27993829. doi:10.1136/annrheumdis-2016-210104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。